Updated preliminary follow-up data from the Phase I/II trial assessing the gene therapy candidate SB-525, being jointly developed by Pfizer and Sangamo Therapeutics, shows clinically relevant and stable improvements in eight patients with hemophilia A, who subsequently experienced a notably reduced need for replacement therapy. A presentation of the new data will be made during the 2019 Congress of the International Society on Thrombosis and Haemostasis.
Preliminary data show gene therapy beneficial to hemophilia A patients
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.